Dr. Ramaprasad Srinivasan highlights the latest treatment advances in kidney cancer
The comprehensive review includes key developments in both clear cell and non-clear cell histology.
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, summarizes the latest advances in the treatment paradigm for patients with renal cell carcinoma (RCC).
At the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared data on one of these advances: a phase 2 study in which the investigational HIF-2α inhibitor MK-6482 showed durable efficacy in patients with Von Hippel-Lindau–associated RCC and non-renal lesions.
In this video, Srinivasan provides a comprehensive review the latest breakthroughs in all areas of RCC, including both clear cell and non-clear cell histology.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
